Q32 Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference | PR Newswire [Video]

, /PRNewswire/ — Q32 Bio Inc. (Nasdaq: QTTB) (“Q32 Bio”), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in a fireside chat at 10:00 a.m. E.T. on Tuesday, November 12, 2024 at Guggenheim’s Inaugural Healthcare Innovation Conference in Boston, MA.

A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio’s website at www.q32bio.com. Archived replays will be available for 90 days following the event.

About Q32 Bio

Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Q32 Bio’s lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives.

Q32 Bio’s program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function for …